<DOC>
	<DOCNO>NCT00036075</DOCNO>
	<brief_summary>The purpose study investigate whether investigational drug , CP-461 , safe effective treatment patient prostate cancer measurable disease .</brief_summary>
	<brief_title>Study Using CP-461 Treat Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Eligibility Criteria : Male 18 year age . Histologically confirm adenocarcinoma prostate , stage D1 D2 . Failure androgen ablation ( orchiectomy LHRH , flutamide ) . Patients must PSA progression progression measurable disease . No prior history systemic chemotherapy . No investigational drug within 4 week study entry . No radiation therapy hormonal therapy within 4 week study entry . No isotope therapy within 6 week study entry . No antiandrogens within 4 week study entry . Patients must continue LHRH . If patient prior surgery , must least 21 day prior study entry , patient must recover side effect . Patients must stop bisphosphonates 28 day prior study entry . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , adequately treated stage I II cancer patient currently remission , disease free least 5 year . Patients must recover major infection and/or surgical procedure , opinion investigator significant active concurrent medical illness , history significant neurologic psychiatric disorder include psychotic disorder , dementia , seizure would preclude protocol treatment survival . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . No chemotherapeutic , biological response modifier , radiation therapy , corticosteroid therapy , hormonal concomitant therapy ( except continuation LHRH ) may give treatment . Patients plan receive concomitant bisphosphonates . ECOG Performance Status = 03 . WBC &gt; = 3500/ul ANC &gt; = 1500/ul . Bilirubin &lt; = ULN . Creatinine &lt; = 2.0 mg/dl . Platelets &gt; = 100,000/ul . ALT AST &lt; 2.5 X ULN .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
</DOC>